FDA Approves First CAR T-Cell Therapy for CLL and SLL
In March 2024, the FDA approved the CAR T-cell therapy lisocabtagene maraleucel (Breyanzi) as a treatment for relapsed or resistant chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Tackling Challenges in CAR-T Fertility Research
John Ligon, MD, an assistant professor in the department of pediatrics at the University of Florida College of Medicine, discussed his view of the main priorities for research in this area.
Around the Helix: Cell and Gene Therapy Company Updates – March 20, 2024
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Standardized Guidelines Are Needed to Collect Data and Counsel Patients Regarding CAR-T and Fertility
John Ligon, MD, an assistant professor in the department of pediatrics at the University of Florida College of Medicine, discussed his team’s early findings on CAR-T and fertility from CIBMTR centers.
First Patient Treated in Trial for NSCLC T-cell Therapy Deltacel Shows Evidence of Tumor Reduction
At the 2-month follow-up PET/CT scan, the patient showed a 6.6% reduction in tumor size.
FDA Makes History With Approval of T-cell Therapy for Melanoma
In February 2024, the FDA approved a tumor-infiltrating lymphocyte therapy called lifileucel for people with advanced melanoma.